Drugs.com - Clinical Trials

Combination Immunotherapy Shrank a Variety of Metastatic Gastrointestinal Cancers

April 1, 2025 -- A new form of tumor infiltrating lymphocyte (TIL) therapy, a form of personalized cancer immunotherapy, dramatically improved the treatment’s effectiveness in patients with metastatic gastrointestinal cancers, according to...

May 12, 2025 - 09:53
 0
Combination Immunotherapy Shrank a Variety of Metastatic Gastrointestinal Cancers
April 1, 2025 -- A new form of tumor infiltrating lymphocyte (TIL) therapy, a form of personalized cancer immunotherapy, dramatically improved the treatment’s effectiveness in patients with metastatic gastrointestinal cancers, according to...
Read More

Tags:

Previous Article

Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track D...

Next Article

FDA Alerts Health Care Providers, Compounders and Consumers of Potential Risks A...

Related Posts

Johnson & Johnson’s TAR-200 Monotherapy Achieves High Disease-Free Survival of More Than 80 Percent in BCG-Unresponsive, High-Risk Papillary NMIBC

Johnson & Johnson’s TAR-200 Monotherapy Achieves High D...

May 12, 2025  0

Linvoseltamab in Combination with Carfilzomib or Bortezomib Shows Promising Initial Results in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma

Linvoseltamab in Combination with Carfilzomib or Bortez...

May 25, 2025  0

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission

Aldeyra Therapeutics Achieves Primary Endpoint in Phase...

May 12, 2025  0